The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells
- 1 February 2014
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 87 (4) , 611-624
Abstract
No abstract availableKeywords
Funding Information
- National Children's Research Centre
This publication has 49 references indexed in Scilit:
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic LeukemiaCancer Research, 2009
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- STI-571 (Imatinib Mesylate) Enhances the Apoptotic Efficacy of Pyrrolo-1,5-Benzoxazepine-6, a Novel Microtubule-Targeting Agent, in Both STI-571-Sensitive and -Resistant Bcr-Abl-Positive Human Chronic Myeloid Leukemia CellsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense SystemPhysiological Reviews, 2006
- Identification of Tubulin as the Molecular Target of Proapoptotic Pyrrolo-1,5-benzoxazepinesMolecular Pharmacology, 2006
- p53 mutations and loss of p53 function confer multidrug resistance in neuroblastomaMedical and Pediatric Oncology, 2000
- Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell linesCancer Chemotherapy and Pharmacology, 2000
- Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.Journal of Clinical Oncology, 1993
- P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for NeuroblastomaNew England Journal of Medicine, 1991